-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Non-alcoholic fatty liver disease (NAFLD) affects 20-30% of the American population.
As we all know, diabetes is an important risk factor for NAFLD
.
Both NAFLD and type 2 diabetes are high-risk patients from steatosis to NASH and then to advanced fibrosis
Non-alcoholic fatty liver disease (NAFLD) affects 20-30% of the American population.
To this end, researchers between January 2004 to January 2008 and December 31 date in the United States Veterans Administration 130 agency offices in the diagnosis of a patient's NAFLD and DM conducted a retrospective cohort study
.
Researchers followed up all patients diagnosed with NAFLD until they developed HCC or died
Manage diagnostic statistics for hypertension
A total of 85,963 NAFLD and DM patients were included in this study
.
During an average follow-up of 10.
This study confirmed that in the NAFLD and DM patient cohort, the use of metformin was associated with a reduced risk of HCC, while combined insulin therapy was associated with an increased risk of HCC
.
Blood glucose control can be used as a biomarker for the risk stratification of NAFLD and HCC in diabetic patients
This study confirmed that in the NAFLD and DM patient cohort, the use of metformin was associated with a reduced risk of HCC, while combined insulin therapy was associated with an increased risk of HCC
Original source:
Jennifer R.
Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease.
Leave a message here
